GeneDx Q3 2026 adjusted net income falls 47% year-over-year to $8.6 million

• GeneDx’s third-quarter 2026 adjusted net income fell 47% year-over-year to $8.6 million.
• Revenue rose 5% year-over-year to $123.1 million; exome and genome revenue increased 12% to $110.4 million.
• Exome and genome test result volume climbed 25% year-over-year to 32,134.
• Expanded its genome testing portfolio with long-read whole genome sequencing and launched an online offering to broaden pediatric exome testing access.
• Maintained 2026 revenue guidance at $475–$490 million while lowering exome and genome revenue growth guidance to at least 17%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-072172), on November 09, 2026, and is solely responsible for the information contained therein.